Pharmacokinetics of lamivudine in cats

American Journal of Veterinary Research

Volumn 65, Issue 6, 2004, Pages 841-846

  Zhang, Weijiang ^a,b   Mauldin, Jeffrey K ^a,c   Schimiedt, Chad W ^a,d   Brockus, Charles W ^a,e   Boundinot, F Douglas ^a,f   McCrackin Stevenson, M A ^a,g  

^a UNIVERSITY OF GEORGIA   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c Culbreth Carr Watson Animal Clinic   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e IOWA STATE UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g Valley Pet Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; LAMIVUDINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CAT DISEASE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUTION; DRUG TRANSPORT; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; NONHUMAN; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CATS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; INJECTIONS, INTRAVENOUS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS;

EID: 3042571648     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.841     Document Type: Article

References (45)

1. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992;43:2059-2064.
2. Pedersen NC, Ho EW, Brown ML, et al. Isolation of a T-lymphotrophic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-793.
3. North TW, North GL, Pedersen NC. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother 1989;33:915-919.
4. North TW, Cronn RC, Remington KM, et al. Characterization of reverse transcriptase from feline immunodeficiency virus. J Biol Chem 1990;265:5121-5128.
5. North TW, Cronn RC, Remington KM, et al. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses. Antimicrob Agents Chemother 1990; 34:1505-1507.
6. Soudeyns H, Yao XJ, Gao Q, et al. Anti-human immunodeficiency virus type a activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-1390.
7. Coates JAV, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992;36:202-205.
8. Coates JAV, Cammack N, Jenkinson HJ, et al. (-)-2′-deoxy-3′-thiacytidine (3TC) is a potent, highly selective inhibitor of HIV-1 and HIV-2 replication in vitro. Antimicrob Agents Chemother 1992; 36:733-739.
9. Chang CN, Doong SL, Zhou JH, et al. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′-3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267:13938-13942.
10. Parker WB, Cheng YC. Mitochondrial toxicity of antiviral nucleoside analogs. J NIH Res 1994;6:57-61.
11. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 1992;264:11934-11937.
12. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991; 39:625-628.
13. Gray NM, Marr CLP, Penn CR, et al. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-a reverse transcriptase and human DNA polymerase γ. Biochem Pharmacol 1995; 50:1043-1051.
14. Lisignoli G, Facchini A, Cattini L, et al. In vitro toxicity of 2′,3′-dideoxy-3′-thiacytidine (BCH189/3TC), a new synthetic anti-HIV-1 nucleoside. Antivir Chem Chemother 1992;3:299-303.
15. Sommadossi JP, Schinazi RF, Chu CK, et al. Comparison of cytotoxicity of the (-)-enantiomer and (+)-enantionter of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol 1992;44:1921-1925.
16. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
17. Schinazi RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875-881.
18. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696-699.
19. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993;90:5653-5656.
20. Back NKT, Nijhuis M, Keulen W, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-4049.
21. Wilson JE, Aulabaugh A, Caligan B, et al. Human immunodeficiency virus type-1 reverse transcriptase: contribution of met-184 binding of nucleoside 5′-triphosphate. J Biol Chem 1996; 271:13656-13662.
22. Keulen W, Back NKT, van Wijk A, et al. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J Virol 1997;71:3346-3350.
23. Wainberg MA, Drosopoulos WC, Salomon H, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996;271:1282-1285.
24. Pandey VN, Kaushik N, Rege N, et al. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 1996;35:2168-2179.
25. Wainberg MA. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia 1997;11(suppl 3):85-88.
26. Hsu M, Inouye P, Rezende L, et al. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 1997;25:4532-4536.
27. Oude Essink BB, Back NKT, Berkhout B. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res 1997;25:3212-3217.
28. Torres RA, Barr MR. Combination antiretroviral therapy for HIV infection. Infect Med 1997;14:142-160.
29. Smyth NR, McCracken C, Gaskell RM, et al. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. J Antimicrob Chemother 1994;34:589-594.
30. McCrackin Stevenson MA, McBroom DG. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. Am J Vet Res 2001;62:588-594.
31. Rajagopalan R, Boudinot FD, Chu CK, et al. Pharmacokinetics of (-)-2′,3′-dideoxy-3′-thiacytidine in woodchucks. Antimicrob Agents Chemother 1996;40:642-645.
32. Rajagopalan R, Moore LE, Schinazi RF, et al. Pharmacokinetics of (-)-β-L2′,3′-dideoxy-3′-thiacytidine in rats. Pharm Sci 1996;2:133-136.
33. Blaney SM, Daniel MJ, Harker AJ, et al. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of non-human primates. Antimicrob Agents Chemother 1995;39:2779-2782.
34. Hussey EK, Donn KH, Daniel MJ, et al. Interspecies scaling and pharmacokinetic parameters of 3TC in humans. J Clin Pharmacol 1994;34:975-977.
35. van Leeuwen R, Lange JM, Hussey EK. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-1475.
36. Stevenson MA, Stiffler KS, Schmiedt CW. One-step placement of a percutaneous nonendoscopic low-profile gastrostomy port in cats. J Am Vet Med Assoc 2000;217:1636-1641.
37. Tyler RD, Cowell RL, Meinkoth JH. Bone marrow. In: Cowell RL, Tyler RD, Meinkoth JH, eds. Diagnostic cytology and hematology of the dog and cat. 2nd ed. St Louis: CV Mosby Inc, 1999;284-304.
38. Brown SA, Finco DR, Boudinot FD, et al. Evaluation of a single injection method, using iohexol, for estimating glomerular filtration rate in cats and dogs. Am J Vet Res 1996;57:105-110.
39. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
40. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995;171:1411-1419.
41. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs 2000;60:701-710.
42. Yamamoto JK, Pu R, Arai M, et al. Feline bone marrow transplantation: its use in FIV-infected cats. Vet Immunol Immunopathol 1998;65:323-351.
43. Arai M, Earl DD, Yamamoto JK. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 2002;85:189-204.
44. Bisset LR, Lutz H, Boni J, et al. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Res 2002; 53:35-45.
45. Zhang W, Mauldin JK, Schmiedt CW, et al. Pharmacokinetics of zidovudine (AZT) in cats. Am J Vet Res 2004;65:835-840.